[Clinical observation of selected CD34(+) cell autologous transplantation in non-Hodgin lymphoma: report of 5 cases].
To investigate the clinical effect of peripheral blood progenitor (PBPC) selected CD34(+) cell autologous transplantation in non-Hodgin lymphoma (NHL) patients. Peripheral blood was collected from 5 NHL patients, 3 males and 2 females, aged 29 (14 - 58), t3 with T cell NHL, 1 with diffused large B cell NHL and 1 with genuine histiocytic lymphoma, 2 at the IIA stage and 3 at the IVB stage, and 4 in their first complete remission (CR1) period, and 1 in partial remission (PR2). CD34(+) cells were collected by magnetic-activated cell sorting system, enriched, and re-infused after pretreatment with chemotherapy and granulocyte-colony stimulating factor. Follow-up was conducted for 1 - 44 months. Magnetic-activated cell sorting resulted in 3.3 log depletion of CD34(-) cells and a median yield of CD34(+) selected cells was reinfused with the dose of 2.0 x 10(6)/kg. The median recovery rate of CD34(+) was 52% and purity rate was 86%. The WBC count became > 0.5 x 10(9)/L and the platelet count became > 20 x 10(9)/L at day 12 and day 19 respectively. Both the event-free and overall survival rate were 80.0% (4/5). One-year survival rate and 5-year estimated survival rate were 80% and 75% respectively. Brings prompt and stable engraftment, autologous selected PBPC CD34(+) cells transplantation may safely improve the clinical outcome of the patients with NHL.